B-cell Non-Hodgkin Lymphoma Market

B-cell Non-Hodgkin Lymphoma Market Size Survey Report – In a Glance

As per the survey report on global B-cell Non-Hodgkin Lymphoma market, the market is projected to foresee a CAGR of CAGR value 8.6% between 2024-2033, and further generate a market size of USD 22.3 billion revenue by the end of 2033. In the year 2024, the market size was valued at USD 8.2 billion revenue.

• The global B-cell Non-Hodgkin Lymphoma market is projected to grow on account of the surging cases of B cell lymphomas.
• In Japan, the B-cell Non-Hodgkin Lymphoma market growth can be attributed to the growing health consciousness.
• KDMI analyst’s growth analysis foresees costly cancer care to challenge the market growth.
• North America, having the highest market share in the B-cell Non-Hodgkin Lymphoma market, is projected to dominate the global market.

B-cell Non-Hodgkin Lymphoma Market Analysis

B-cell Non-Hodgkin Lymphoma (B-cell NHL) is a type of malignancy that affects the lymphatic system targeting B cells which plays a key role in the immune defense of the body. The surge in B-cell lymphoma cases, particularly fast progressing types is propelling the B-cell NHL market by increasing the need for advanced treatments or therapies. Across the globe, diffuse large B cell lymphoma makes up roughly one-third of all non-Hodgkin lymphoma subtypes with incidence rates differing by country from 20% to 50%. However, advancements in monoclonal antibodies, CAR-T solutions, and targeted medications are the key drivers complemented by better diagnostics and expanding trials for broader treatment adoption. Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), are some of the significant parties in the global market for B-cell Non-Hodgkin Lymphoma .

Analyst’s Observation on Japan B-cell Non-Hodgkin Lymphoma Market Survey

In Japan, the market growth for B-cell Non-Hodgkin Lymphoma can be attributed to the growing health consciousness. More people are becoming health-aware in the country, increasing the demand for wellness products and services. This shift is shaped by people embracing active lifestyles, mental wellness, and balanced nutrition. However, this increasing public awareness about health and disease has spurred significant market changes. Projections indicate that the health and consumer health market will experience a compound annual growth rate (CAGR) of 3.96% from 2024 to 2032, ultimately indicating a rise in the B-cell Non-Hodgkin Lymphoma market. Kite Pharma, Inc., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd.,are some of the significant parties in the market for B-cell Non-Hodgkin Lymphoma in Japan.

B-cell Non-Hodgkin Lymphoma Market Growth Drivers and Challenges

Growth Drivers

Progress in healthcare solutions:

Ongoing processes in treatment methods or therapeutic solutions have greatly benefited B-cell Non-Hodgkin lymphoma patients. Also, breakthroughs in target therapies, CAR-T cell techniques, and immunotherapy have become crucial in combating the disease stimulating market growth, and introducing more effective options. Effective treatments which include monoclonal antibodies and small molecule inhibitors offer promising outcomes with opportunities for further improvement, reduced toxicity, and resistance management. The global medical sector experienced significant development surpassing almost$12 trillion in 2022. Moreover, advanced diagnostic tools, personalized approaches and novel pharmaceuticals boost efficiency, mitigate side effects and tackle resistance. This results in higher adoption rates, better patient prognosis and market progression. Therefore, progress in healthcare solutions such as targeted treatments and immunotherapy is accelerating the B-cell Non-Hodgkin lymphoma market.

Expanding investments by key players:

Key market players leverage strategies like innovative product launches and strategic partnerships which offers a competitive edge in the coming years. Collaborations between established companies and smaller enterprises drive revenue gains while private investments in emerging companies support long term development. Financial backing brings about breakthroughs in CAR-T cell treatments, immunotherapy, and personalized medicine improving patient care and market reach. With continuous discoveries and innovations, excitement for upcoming cancer treatment advancements is increasing. According to reports, developed nations allocate between 0.1–0.2% of the gross domestic product (GDP) and on average, cancer service spending represent almost 0.8% of the nation’s GDP. Therefore, expanding investments by key players are catalyzing the B-cell Non-Hodgkin lymphoma market through rapid drug development, advancing target therapy research, and scaling up clinical trials.

Restraints

Costly cancer care:

The high cost of cancer treatments has slowed the B-cell Non-Hodgkin lymphoma market. Often, many patients fail to afford advanced cancer therapies or treatments due to inadequate financial assistance and a lack of flexible payment schemes. Addressing this major challenge is important for better accessibility and overall market progression.

Shortage of skilled workforce:

The limited availability of qualified experts or trained healthcare professionals with appropriate knowledge of cancer treatment techniques might impede the development of the global B-cell Non-Hodgkin lymphoma market throughout the forecast period. This is because the shortage of trained experts limits proper diagnosis, reduces treatment quality, and decreases the adoption of cutting-edge technologies, thereby, restricting the global market.

B-cell Non-Hodgkin Lymphoma Market Segmentation

Our experts at KD Market Insights have segmented the global B-cell Non-Hodgkin Lymphoma market research report as:

B-cell Non-Hodgkin Lymphoma Market Regional Synopsis

North America steers the way in the B-cell Non-Hodgkin Lymphoma market and is majorly driven by its significant increase in pharmaceutical research and development activities. Besides that, increasing cancer patient pool, advanced facilities, growing research institutions, well-developed healthcare systems, existence of major market players, increased awareness among the public, and favorable regulatory policies in Canada and the United States further drive the market within the region. The United States holds the largest share of the regional B-cell Non-Hodgkin Lymphoma market within the given period because of the increasing cancer prevalence, presence of pharmaceutical companies, growing advancements in treatment options, and increasing adoption of innovative treatments along with a promising drug development pipeline in the country. In the United States, near about 2,001,140 new cancer cases and 611,720 cancer deaths were already expected to occur in 2024.

Asia-Pacific (APAC) is encountering the quickest market surge during the forecasted period. The region functions as a central point for pharmaceutical businesses. This is mainly due to expansive distribution channels and trade connections. Furthermore, the market is also driven by the improved healthcare facilities, growing prevalence of malignancies, increasing use of generic drugs, economic growth, consumer demands, and progressing healthcare framework. India is also upgrading the B-cell Non-Hodgkin Lymphoma market due to its massive population, surging number of cancer patients, rising public awareness, greater healthcare investments and strengthening healthcare systems. In addition to that, Japan’s healthcare investments are likely to expand at a rate beyond its expected growth capacity. China is also contributing a significant part to the regional market. It has implemented the world’s largest planned urban transformation program, thereby, promoting healthcare development. Also, numerous medical research and drug developments have supported its overall healthcare framework and economic growth goals.

In Europe, several government organizations are supporting early detection, enhanced patient outcomes, increasing medical spending, and preventive measures for B-cell Non-Hodgkin Lymphoma are mainly forecasted to drive market expansion in the near future. Moreover, the UK is at the forefront of the development of the market in the region due to its increasingly improved diagnostics and strong healthcare policies. Various factors are responsible for the market evolution in the area such as the availability of cutting-edge therapies, growing public awareness about cancers, and expanding availability of medical solutions.

As per our analysts at KD Market Insights, the following five players lead the North America B-cell Non-Hodgkin Lymphoma market growth:

• Pfizer Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Merck & Co., Inc. (U.S.)
• Cipla Inc. (U.S.)
• Abbott (U.S.)

B-cell Non-Hodgkin Lymphoma Market Competitive Landscape

Some of the key players who top the global B-cell Non-Hodgkin Lymphoma market share:

• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Eli Lilly and Company (U.S.)
• Merck & Co., Inc. (U.S.)
• AbbVie Inc. (Ireland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Cipla Inc. (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Merck KGaA (Germany)
• LEO Pharma A/S (Denmark)
• Bausch Health Companies Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.S.)

1. Executive Summary
   1. Market Overview
   2. Key Findings
   3. Market Trends
   4. Market Outlook
2. Introduction
   1. Scope of the Report
   2. Research Methodology
   3. Definitions and Assumptions
   4. Acronyms and Abbreviations
3. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
   4. Challenges
4. Global B-cell Non-Hodgkin Lymphoma Market
   1. Market Overview
   2. Market Size and Forecast
   3. Market Segmentation
      1. By Type
      2. By Treatment type
      3. By Route of administration
      4. By End-user
      5. By Distribution channel
      6. By Region
5. Market Segmentation by Type
   1. 1. B-Cell Lymphomas
      2. T-Cell Lymphoma
      3. Others
6. Market Segmentation by Treatment type
   1. 1. Chemotherapy
      2. Targeted Therapy
      3. Others
7. Market Segmentation by Route of administration
   1. 1. Oral
      2. Parenteral
      3. Others
8. Market Segmentation by End-user
   1. 1. Hospitals
      2. Homecare
      3. Speciality Centres
      4. Others
9. Market Segmentation by Distribution channel
   1. 1. Hospital Pharmacy
      2. Online Pharmacy
      3. Retail Pharmacy
      4. Others
10. Regional Analysis
    1. North America
       1. United States
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       2. Canada
          1. Market Size and Forecast
          2. Key Trends and Developments
       3. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       4. Mexico
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
    2. Europe
       1. United Kingdom
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       2. Germany
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       3. France
          1. Market Size and Forecast
          2. Key Trends and Developments
       4. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       5. Italy
          1. Market Size and Forecast
          2. Key Trends and Developments
       6. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       7. Spain
          1. Market Size and Forecast
          2. Key Trends and Developments
       8. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       9. Rest of Europe
          1. Market Size and Forecast
          2. Key Trends and Developments
    3. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
    4. Asia Pacific
       1. China
          1. Market Size and Forecast
          2. Key Trends and Developments
       2. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       3. Japan
          1. Market Size and Forecast
          2. Key Trends and Developments
       4. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       5. India
          1. Market Size and Forecast
          2. Key Trends and Developments
       6. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       7. Australia
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
          4. South Korea
          5. Market Size and Forecast
          6. Key Trends and Developments
       8. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       9. Rest of Asia Pacific
          1. Market Size and Forecast
          2. Key Trends and Developments
    5. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
    6. Latin America
       1. Brazil
          1. Market Size and Forecast
          2. Key Trends and Developments
       2. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       3. Argentina
          1. Market Size and Forecast
          2. Key Trends and Developments
       4. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       5. Colombia
          1. Market Size and Forecast
          2. Key Trends and Developments
       6. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       7. Rest of Latin America
          1. Market Size and Forecast
          2. Key Trends and Developments
    7. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
    8. Middle East & Africa
       1. South Africa
          1. Market Size and Forecast
          2. Key Trends and Developments
       2. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       3. Saudi Arabia
          1. Market Size and Forecast
          2. Key Trends and Developments
       4. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       5. UAE
          1. Market Size and Forecast
          2. Key Trends and Developments
       6. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
       7. Rest of Middle East & Africa
          1. Market Size and Forecast
          2. Key Trends and Developments
          3. Market Analysis by Type, Treatment type, Route of administration, End-user and Distribution channel
11. Competitive Landscape
    1. Market Share Analysis
    2. Company Profiles
    3. Sanofi (France)
    4. Pfizer Inc. (U.S.)
    5. GlaxoSmithKline plc (U.K.)
    6. Novartis AG (Switzerland)
    7. Bayer AG (Germany)
    8. Eli Lilly and Company (U.S.)
    9. Merck & Co., Inc. (U.S.)
    10. AbbVie Inc. (Ireland)
    11. AstraZeneca (U.K.)
    12. Johnson & Johnson Private Limited (U.S.)
    13. Cipla Inc. (U.S.)
    14. Abbott (U.S.)
12. Strategic Recommendations
13. Appendix
    1. List of Tables
    2. List of Figures
14. References